

Initial Review: Notification of IRB Approval/Activation Protocol #: 2015P000904/MGH

Date: December 2, 2015

To: Richard Louis Maas, MD
BWH
Medicine / Genetics

Joel Krier, MD, MSC
BWH
Medicine / Genetics

Lael Yonker
MGH
Pediatric Service

From: Partners Human Research Committee
116 Huntington Avenue, Suite 1002
Boston, MA 02116

Title of Protocol: Genomic Evaluation of Disease

Sponsor/Funding Support:

Proposal Title: Genetics Div. Discretionary
Name: Sundry

Study Population: Adults
Consent/Authorization: Required
Documentation of Consent: Written
Informed Consent From: Adult Subject
Informed Consent By: Licensed Physician Investigator
Non-Physician Investigator
Other Study Staff

Study Population: Children
Children Risk Assessment: 45 CFR 46.404
Consent/Authorization: Required
Documentation of Consent: Written
Informed Consent From: One Parent/Guardian for Child

Informed Consent By: Licensed Physician Investigator
Non-Physician Investigator
Other Study Staff
Assent: Required
Documentation of Assent: Written Assent
Assent From: Children Capable of Assent
IRB Review Type: Full
IRB Approval Date: 12/2/2015
Approval Activation Date: 12/2/2015
IRB Expiration Date: 11/10/2016

This project has been reviewed by MGH IRB . During the review of this project, the IRB specifically considered (i) the risks and anticipated benefits, if any, to subjects; (ii) the selection of subjects; (iii) the procedures for obtaining and documenting informed consent; (iv) the safety of subjects; and (v) the privacy of subjects and confidentiality of the data.

Please note that if an IRB member had a conflict of interest with regard to the review of this project, consistent with IRB policies and procedures, the member was required to leave the room during the discussion and vote on this project except to provide information requested by the IRB.

The IRB has reviewed and approved the following documents:

Protocol Summary (version date 11/24/15)

Consent Form (2)

Assent Form (1)

Recruitment Letter (3)

Phone Script (2)

Instrument/Questionnaire (1)

Physician Letter

Post Skin Biopsy Care Instructions

BioBank Protocol Summary

Opt Out Card

As Principal Investigator, you are responsible for ensuring that this project is conducted in compliance with all applicable federal, state and local laws and regulations, institutional policies, and requirements of the IRB, which include, but are not limited to, the following:

1. Submission of any and all proposed changes to this project (e.g., protocol, recruitment materials, consent form, status of the study, etc.) to the IRB for review and approval prior to initiation of the change(s), except where necessary to eliminate apparent immediate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB as an unanticipated problem.
2. Submission of continuing review submissions for re-approval of the project prior to expiration of IRB approval and a final continuing review submission when the project has been completed.
3. Submission of any and all unanticipated problems, including adverse event(s) in accordance with the IRB's policy on reporting unanticipated problems including adverse events.
4. Obtaining informed consent from subjects or their legally authorized representative prior to initiation of research procedures when and as required by the IRB and, when applicable, documenting informed

consent using the current IRB approved consent form(s) with the IRB-approval stamp in the document footer.

5. Informing all investigators and study staff listed on the project of changes and unanticipated problems, including adverse events, involving risks to subjects or others.
6. When investigator financial disclosure forms are required, updating your financial interests in Insight and for informing all site responsible investigators, co-investigators and any other members of the study staff identified by you as being responsible for the design, conduct, or reporting of this research study of their obligation to update their financial interest disclosures in Insight if (a) they have acquired new financial interests related to the study and/or (b) any of their previously reported financial interests related to the study have changed.

The IRB has the authority to terminate projects that are not in compliance with these requirements.

Questions related to this project may be directed to Fred Syllien, FSYLLIEN@PARTNERS.ORG, 617-424-4124.